Diosmetin as a Promising Anticancer Agent: Mechanisms, Structural Optimization, and Advanced Delivery Systems
- 1Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital) , , ,
- 2The First Clinical College of Shandong University of Traditional Chinese Medicine , , ,
- 3Qingdao University of Science and Technology , , ,
Abstract
Diosmetin (Dio) is a natural flavonoid with broad-spectrum anticancer activity against various malignancies through mechanisms involving cell cycle arrest, apoptosis induction, metastasis inhibition, and modulation of oncogenic signaling pathways such as STAT3/c-Myc and PI3K/AKT/mTOR; with the exception of CDK2, which has been proposed as a direct target in esophageal squamous cell carcinoma, no other direct molecular targets of diosmetin have been identified to date. It also exhibits synergistic efficacy with reduced toxicity when combined with radiotherapy or chemotherapy. However, clinical translation is severely hampered by poor water solubility, low bioavailability, and unidentified direct molecular targets. Structural modifications (esterification, etherification, phosphorylation) and advanced drug delivery systems (SMEDDS, targeted liposomes, composite nanoparticles) offer promising strategies to overcome these limitations. This review provides an integrated framework covering the complete chain from extraction and chemical derivatization to formulation strategies and anticancer mechanisms, with critical analysis of current translational bottlenecks, particularly the disconnect between in vitro and in vivo findings. By integrating chemical optimization with pharmacological mechanisms, this review aims to provide a theoretical foundation to inform and guide future preclinical and translational research on Dio as a potential adjunct to existing cancer therapies. While some of these strategies have been validated in cancer models, others have been demonstrated in noncancer settings and await translation to oncology.
Related
- Targeting oral cancer with curcumin and its structural analogs: molecular mechanisms, pharmacokinetic optimization, and clinical translation.
- Flavone-Based Anticancer Agents: Advances in Structure–Activity Relationships and Multitarget Mechanisms for Drug Design (2015–Present)
- Molecular mechanisms involved in the anticancer activities of probiotics and postbiotics.
- Risk Factors and Pathophysiological Mechanisms in Drug-Induced Interstitial Lung Disease Associated With Novel Anticancer Agents: A Scoping Review (2016-2026)
- Molecular Mechanisms of the Anticancer Activity of Hinokitiol in C32 Melanoma Cells: Transcriptomic Analysis and Modulation by a Static Magnetic Field
BibTeX
@article{long2026diosmetin,
title = {{Diosmetin as a Promising Anticancer Agent: Mechanisms, Structural Optimization, and Advanced Delivery Systems}},
author = {Lin Long and Yuning Liu and Jianhua Zang and Gaoyang Lin and Chuanlong Guo and Jun Xiao},
journal = {ACS Omega},
year = {2026},
month = oct,
doi = {10.1021/acsomega.6c03859},
url = {https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c03859/5454215/Diosmetin-as-a-Promising-Anticancer-Agent},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Diosmetin as a Promising Anticancer Agent: Mechanisms, Structural Optimization, and Advanced Delivery Systems
AU - Lin Long
AU - Yuning Liu
AU - Jianhua Zang
AU - Gaoyang Lin
AU - Chuanlong Guo
AU - Jun Xiao
PY - 2026
DA - 2026/10/20
JO - ACS Omega
DO - 10.1021/acsomega.6c03859
UR - https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c03859/5454215/Diosmetin-as-a-Promising-Anticancer-Agent
AB - Diosmetin (Dio) is a natural flavonoid with broad-spectrum anticancer activity against various malignancies through mechanisms involving cell cycle arrest, apoptosis induction, metastasis inhibition, and modulation of oncogenic signaling pathways such as STAT3/c-Myc and PI3K/AKT/mTOR; with the exception of CDK2, which has been proposed as a direct target in esophageal squamous cell carcinoma, no other direct molecular targets of diosmetin have been identified to date. It also exhibits synergistic efficacy with reduced toxicity when combined with radiotherapy or chemotherapy. However, clinical translation is severely hampered by poor water solubility, low bioavailability, and unidentified direct molecular targets. Structural modifications (esterification, etherification, phosphorylation) and advanced drug delivery systems (SMEDDS, targeted liposomes, composite nanoparticles) offer promising strategies to overcome these limitations. This review provides an integrated framework covering the complete chain from extraction and chemical derivatization to formulation strategies and anticancer mechanisms, with critical analysis of current translational bottlenecks, particularly the disconnect between in vitro and in vivo findings. By integrating chemical optimization with pharmacological mechanisms, this review aims to provide a theoretical foundation to inform and guide future preclinical and translational research on Dio as a potential adjunct to existing cancer therapies. While some of these strategies have been validated in cancer models, others have been demonstrated in noncancer settings and await translation to oncology.
SN - 2470-1343
ER -